The first European interdisciplinary Ewing sarcoma research summit

Heinrich Kovar, Javier Alonso, Pierre Aman, Dave N T Aryee, Jozef Ban, Sue A. Burchill, Stefan Burdach, Enrique De Alava, Olivier Delattre, Uta Dirksen, Argyro Fourtouna, Simone Fulda, Lee J. Helman, David Herrero-Martin, Pancras C. Pancras, Udo Kontny, Elizabeth R. Lawlor, Stephen L. Lessnick, Antonio Llombart-Bosch, Markus MetzlerRichard Moriggl, Stephan Niedan, Jenny Potratz, Françoise Redini, Günther H. Günther, Lucia T. Riedmann, Claudia Rossig, Beat W. Schäfer, Raphaela Schwentner, Katia Scotlandi, Poul H. Sorensen, Martin S. Staege, Franck Tirode, Jeffrey Toretsky, Selena Ventura, Angelika Eggert, Ruth Ladenstein

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.

Original languageEnglish
Article numberArticle 54
JournalFrontiers in Oncology
Volume2 MAY
DOIs
Publication statusPublished - 2012

Fingerprint

Ewing's Sarcoma
Research
Neoplasms
Clinical Trials
Clinical Protocols
Child Care
Sarcoma
Survival Rate
Therapeutics
Pharmaceutical Preparations

Keywords

  • Animal models
  • Biomarkers
  • Drug screen
  • Epigenetics
  • Ewing sarcoma
  • Genomics
  • Prognosis
  • Sarcomagenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kovar, H., Alonso, J., Aman, P., Aryee, D. N. T., Ban, J., Burchill, S. A., ... Ladenstein, R. (2012). The first European interdisciplinary Ewing sarcoma research summit. Frontiers in Oncology, 2 MAY, [Article 54]. https://doi.org/10.3389/fonc.2012.00054

The first European interdisciplinary Ewing sarcoma research summit. / Kovar, Heinrich; Alonso, Javier; Aman, Pierre; Aryee, Dave N T; Ban, Jozef; Burchill, Sue A.; Burdach, Stefan; De Alava, Enrique; Delattre, Olivier; Dirksen, Uta; Fourtouna, Argyro; Fulda, Simone; Helman, Lee J.; Herrero-Martin, David; Pancras, Pancras C.; Kontny, Udo; Lawlor, Elizabeth R.; Lessnick, Stephen L.; Llombart-Bosch, Antonio; Metzler, Markus; Moriggl, Richard; Niedan, Stephan; Potratz, Jenny; Redini, Françoise; Günther, Günther H.; Riedmann, Lucia T.; Rossig, Claudia; Schäfer, Beat W.; Schwentner, Raphaela; Scotlandi, Katia; Sorensen, Poul H.; Staege, Martin S.; Tirode, Franck; Toretsky, Jeffrey; Ventura, Selena; Eggert, Angelika; Ladenstein, Ruth.

In: Frontiers in Oncology, Vol. 2 MAY, Article 54, 2012.

Research output: Contribution to journalArticle

Kovar, H, Alonso, J, Aman, P, Aryee, DNT, Ban, J, Burchill, SA, Burdach, S, De Alava, E, Delattre, O, Dirksen, U, Fourtouna, A, Fulda, S, Helman, LJ, Herrero-Martin, D, Pancras, PC, Kontny, U, Lawlor, ER, Lessnick, SL, Llombart-Bosch, A, Metzler, M, Moriggl, R, Niedan, S, Potratz, J, Redini, F, Günther, GH, Riedmann, LT, Rossig, C, Schäfer, BW, Schwentner, R, Scotlandi, K, Sorensen, PH, Staege, MS, Tirode, F, Toretsky, J, Ventura, S, Eggert, A & Ladenstein, R 2012, 'The first European interdisciplinary Ewing sarcoma research summit', Frontiers in Oncology, vol. 2 MAY, Article 54. https://doi.org/10.3389/fonc.2012.00054
Kovar H, Alonso J, Aman P, Aryee DNT, Ban J, Burchill SA et al. The first European interdisciplinary Ewing sarcoma research summit. Frontiers in Oncology. 2012;2 MAY. Article 54. https://doi.org/10.3389/fonc.2012.00054
Kovar, Heinrich ; Alonso, Javier ; Aman, Pierre ; Aryee, Dave N T ; Ban, Jozef ; Burchill, Sue A. ; Burdach, Stefan ; De Alava, Enrique ; Delattre, Olivier ; Dirksen, Uta ; Fourtouna, Argyro ; Fulda, Simone ; Helman, Lee J. ; Herrero-Martin, David ; Pancras, Pancras C. ; Kontny, Udo ; Lawlor, Elizabeth R. ; Lessnick, Stephen L. ; Llombart-Bosch, Antonio ; Metzler, Markus ; Moriggl, Richard ; Niedan, Stephan ; Potratz, Jenny ; Redini, Françoise ; Günther, Günther H. ; Riedmann, Lucia T. ; Rossig, Claudia ; Schäfer, Beat W. ; Schwentner, Raphaela ; Scotlandi, Katia ; Sorensen, Poul H. ; Staege, Martin S. ; Tirode, Franck ; Toretsky, Jeffrey ; Ventura, Selena ; Eggert, Angelika ; Ladenstein, Ruth. / The first European interdisciplinary Ewing sarcoma research summit. In: Frontiers in Oncology. 2012 ; Vol. 2 MAY.
@article{070091fb743543ddb561f234874ee9c9,
title = "The first European interdisciplinary Ewing sarcoma research summit",
abstract = "The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20{\%}. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.",
keywords = "Animal models, Biomarkers, Drug screen, Epigenetics, Ewing sarcoma, Genomics, Prognosis, Sarcomagenesis",
author = "Heinrich Kovar and Javier Alonso and Pierre Aman and Aryee, {Dave N T} and Jozef Ban and Burchill, {Sue A.} and Stefan Burdach and {De Alava}, Enrique and Olivier Delattre and Uta Dirksen and Argyro Fourtouna and Simone Fulda and Helman, {Lee J.} and David Herrero-Martin and Pancras, {Pancras C.} and Udo Kontny and Lawlor, {Elizabeth R.} and Lessnick, {Stephen L.} and Antonio Llombart-Bosch and Markus Metzler and Richard Moriggl and Stephan Niedan and Jenny Potratz and Fran{\cc}oise Redini and G{\"u}nther, {G{\"u}nther H.} and Riedmann, {Lucia T.} and Claudia Rossig and Sch{\"a}fer, {Beat W.} and Raphaela Schwentner and Katia Scotlandi and Sorensen, {Poul H.} and Staege, {Martin S.} and Franck Tirode and Jeffrey Toretsky and Selena Ventura and Angelika Eggert and Ruth Ladenstein",
year = "2012",
doi = "10.3389/fonc.2012.00054",
language = "English",
volume = "2 MAY",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The first European interdisciplinary Ewing sarcoma research summit

AU - Kovar, Heinrich

AU - Alonso, Javier

AU - Aman, Pierre

AU - Aryee, Dave N T

AU - Ban, Jozef

AU - Burchill, Sue A.

AU - Burdach, Stefan

AU - De Alava, Enrique

AU - Delattre, Olivier

AU - Dirksen, Uta

AU - Fourtouna, Argyro

AU - Fulda, Simone

AU - Helman, Lee J.

AU - Herrero-Martin, David

AU - Pancras, Pancras C.

AU - Kontny, Udo

AU - Lawlor, Elizabeth R.

AU - Lessnick, Stephen L.

AU - Llombart-Bosch, Antonio

AU - Metzler, Markus

AU - Moriggl, Richard

AU - Niedan, Stephan

AU - Potratz, Jenny

AU - Redini, Françoise

AU - Günther, Günther H.

AU - Riedmann, Lucia T.

AU - Rossig, Claudia

AU - Schäfer, Beat W.

AU - Schwentner, Raphaela

AU - Scotlandi, Katia

AU - Sorensen, Poul H.

AU - Staege, Martin S.

AU - Tirode, Franck

AU - Toretsky, Jeffrey

AU - Ventura, Selena

AU - Eggert, Angelika

AU - Ladenstein, Ruth

PY - 2012

Y1 - 2012

N2 - The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.

AB - The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.

KW - Animal models

KW - Biomarkers

KW - Drug screen

KW - Epigenetics

KW - Ewing sarcoma

KW - Genomics

KW - Prognosis

KW - Sarcomagenesis

UR - http://www.scopus.com/inward/record.url?scp=84870447721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870447721&partnerID=8YFLogxK

U2 - 10.3389/fonc.2012.00054

DO - 10.3389/fonc.2012.00054

M3 - Article

AN - SCOPUS:84870447721

VL - 2 MAY

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 54

ER -